Advances in the Treatment of Non-Hodgkin’s Lymphoma

New and Novel Agents for the Treatment of Non-Hodgkin's Lymphoma: A Report from the 2008 Meeting of the American Society of Hematology

The 2008 ASH meeting featured several reports of new agents that are showing promise in the treatment of Non-Hodgkin's Lymphoma (NHL).

Revlimid for Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma

Revlimid® (lenalidomide) is an orally administered derivative of thalidomide, a very active agent for the treatment of multiple myeloma. Revlimid also has anti-angiogeneic properties as well as numerous possible immune and biologic properties. Clinical trials have also documented activity for Revlimid in renal cell carcinoma, myelodysplastic syndromes, and CLL. Revlimid also has significant activity in patients with relapsed or refractory aggressive NHL, including mantle cell lymphoma. | @ltaLINK | @ltaSEARCH